Last reviewed · How we verify
Temozolomide & Radiation Therapy — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Temozolomide & Radiation Therapy (Temozolomide & Radiation Therapy) — Myrexis Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Temozolomide & Radiation Therapy TARGET | Temozolomide & Radiation Therapy | Myrexis Inc. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Temozolomide & Radiation Therapy CI watch — RSS
- Temozolomide & Radiation Therapy CI watch — Atom
- Temozolomide & Radiation Therapy CI watch — JSON
- Temozolomide & Radiation Therapy alone — RSS
Cite this brief
Drug Landscape (2026). Temozolomide & Radiation Therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/temozolomide-radiation-therapy. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab